CytoDyn files protocol for extended access to PRO 140 for patients who reach end of trial
CytoDyn announced it has filed a new roll-over protocol allowing all ongoing patients who reach the end of the Phase 3 combination study to continue receiving PRO 140. The primary intent of this roll-over protocol is to provide PRO 140 for a second and other patients, who has completed the study. October 24, 2016